TRANSSPHENOIDAL ADENOMECTOMY FOR GROWTH HORMONE-SECRETING PITUITARY-ADENOMAS IN ACROMEGALY - OUTCOME ANALYSIS AND DETERMINANTS OF FAILURE

被引:104
作者
TINDALL, GT
OYESIKU, NM
WATTS, NB
CLARK, RV
CHRISTY, JH
ADAMS, DA
机构
[1] EMORY UNIV, SCH MED, PROGRAM NEUROSCI, ATLANTA, GA 30322 USA
[2] EMORY UNIV, SCH MED, DEPT MED ENDOCRINOL, ATLANTA, GA 30322 USA
关键词
ACROMEGALY; GROWTH HORMONE; PITUITARY ADENOMA; TRANSSPHENOIDAL SURGERY; OUTCOME;
D O I
10.3171/jns.1993.78.2.0205
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The results of transsphenoidal adenomectomy for growth hormone (GH)-secreting pituitary adenomas in acromegaly performed over a 17-year period were analyzed retrospectively to determine which preoperative factors significantly influenced the long-term surgical outcome. These variables were then used to develop a logistic regression model to determine the probability of surgical failure. The series consisted of 103 patients. Long-term follow-up study (mean duration 102 +/- 64 months) was performed to derive outcome analysis and determinants of failure. Surgical control was defined as a long-term postoperative serum basal GH level of less than 5 mug/liter, a long-term postoperative serum somatomedin C (SM-C) level of less than 2.2 U/ml, and a favorable clinical response. Eighteen (17.5%) patients did not meet these criteria. The overall control rate by the GH criteria was 81.3% and by the SM-C criteria 76.2%. By multivariate logistic regression analysis, tumor stage was the strongest predictor of outcome (p < 0.05). The preoperative GH level, tumor grade, and preoperative SM-C level were significant univariate predictors (p < 0.05). There were statistically significant differences in mean preoperative GH and SM-C levels (p < 0.05, t-test) and tumor stage (p < 0.05, chi-squared test) between patients whose acromegaly was controlled by surgery and those whose acromegaly was not. Furthermore, estimates were derived of the probability of surgical failure based on preoperative GH level, preoperative SM-C level, and tumor grade and stage. The authors believe these findings will enhance clinical decision-making for neurosurgeons considering transsphenoidal microsurgery in patients with acromegaly.
引用
收藏
页码:205 / 215
页数:11
相关论文
共 65 条
[31]  
KNAPPE G, 1982, ENDOKRINOLOGIE, V79, P423
[32]   SMS-201-995 INDUCES A CONTINUOUS DECLINE IN CIRCULATING GROWTH-HORMONE AND SOMATOMEDIN-C LEVELS DURING THERAPY OF ACROMEGALIC PATIENTS FOR OVER 2 YEARS [J].
LAMBERTS, SWJ ;
UITTERLINDEN, P ;
DELPOZO, E .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1987, 65 (04) :703-710
[33]   LONG-TERM TREATMENT OF ACROMEGALY WITH THE SOMATOSTATIN ANALOG SMS 201-995 [J].
LAMBERTS, SWJ ;
UITTERLINDEN, P ;
VERSCHOOR, L ;
VANDONGEN, KJ ;
DELPOZO, E .
NEW ENGLAND JOURNAL OF MEDICINE, 1985, 313 (25) :1576-1578
[34]  
LANDOLT AM, 1987, GROWTH HORMONE GROWT, P224
[35]   NEUROSURGICAL MANAGEMENT OF ACROMEGALY - RESULTS IN 82 PATIENTS TREATED BETWEEN 1972 AND 1977 [J].
LAWS, ER ;
PIEPGRAS, DG ;
RANDALL, RV ;
ABBOUD, CF .
JOURNAL OF NEUROSURGERY, 1979, 50 (04) :454-461
[36]  
LAWS ER, 1987, ACROMEGALY CENTURY S, P241
[37]   INVESTIGATION OF THE CRITERIA FOR ASSESSING THE OUTCOME OF TREATMENT IN ACROMEGALY [J].
LINDHOLM, J ;
GIWERCMAN, B ;
GIWERCMAN, A ;
ASTRUP, J ;
BJERRE, P ;
SKAKKEBAEK, NE .
CLINICAL ENDOCRINOLOGY, 1987, 27 (05) :553-562
[38]   EVALUATION OF SELECTIVE TRANS-SPHENOIDAL ADENOMECTOMY BY ENDOCRINOLOGICAL TESTING AND SOMATOMEDIN-C MEASUREMENT IN ACROMEGALY [J].
LOSA, M ;
OECKLER, R ;
SCHOPOHL, J ;
MULLER, OA ;
ALBALOPEZ, J ;
VONWERDER, K .
JOURNAL OF NEUROSURGERY, 1989, 70 (04) :561-567
[39]   THE CHOICE OF TREATMENT AFTER INCOMPLETE ADENOMECTOMY IN ACROMEGALY - PROTON - VERSUS HIGHVOLTAGE RADIATION [J].
LUDECKE, DK ;
LUTZ, BS ;
NIEDWOROK, G .
ACTA NEUROCHIRURGICA, 1989, 96 (1-2) :32-38
[40]   MEDICAL PROGRESS - ACROMEGALY [J].
MELMED, S .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (14) :966-977